[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,85,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100649624","phase-1-a-study-of-hl40626s-tablets-in-healthy-adults-100649624",false,"NCT07736586","A Study of HL40626S Tablets in Healthy Adults","A Randomized, Double-Blind, Placebo-Controlled, Sequential Group, 2-Part, Phase Ι Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HL40626S Tablets Following Oral Administration of Single and Multiple Ascending Doses to Healthy Adult Participants.","Inclusion Criteria:\n\n1. Capable of understanding the written informed consent document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.\n2. Between the ages of 18.0 and 55.0 years (inclusive) at the time of Screening.\n3. BMI between 18.0 and 32.0 kg\u002Fm2 (inclusive) at the time of Screening, with a body weight ≥ 50 kg.\n4. In good general health, as determined by the Investigator.\n5. Female participants must be non-pregnant and non-lactating.\n6. Female participants must be of non-childbearing potential, or agree to use dual contraception methods (female participants exclusively in same-sex relationships are exempt from the above contraception requirements), and abstain from ova (egg) donation throughout the entire duration of the study and for at least 90 days after the last dose, and have negative pregnancy test results at Screening (serum) and Day -1 (urine). (Note: As this is a first-in-human \\[FIH\\] study, the applicable t₁\u002F₂ and corresponding restriction period may be adjusted based on emerging PK data).\n7. Male participants with female partners of reproductive potential must agree to practice complete abstinence or to use a condom (male participant) plus an additional highly effective method (female partner) of contraception for the duration of the study and for at least 90 days after last dosing (Male participants exclusively in same-sex relationships are exempt from the above contraception requirements); all male participants must also agree to refrain from sperm donation for at least 90 days after the last dose. (Note: As this is a FIH study, the applicable t₁\u002F₂ and corresponding restriction period will be adjusted based on real-time PK data).\n\nExclusion Criteria:\n\n1. Clinically significant abnormal medical history, such as gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, drug hypersensitivity, as determined by the Investigator, any abnormal findings on physical examination, VS measurements, ECG or laboratory tests at Screening, Admission or pre dose on Day 1 that, in the opinion of the Investigator, could jeopardize achieving the study objectives and\u002For compromise the participant's safety.\n2. Any of the following ECG findings at Screening, Admission and\u002For pre dose on Day 1:\n\n   1. Any out-of-range ECG parameter(s) or abnormal finding(s) considered clinically significant by the Investigator.\n   2. Any ECG finding that, in the opinion of the Investigator, may compromise interpretation of ECG for cardiac safety assessments and\u002For complicate interpretation of events that may occur post dose (e.g., QT not accurately measurable, conduction abnormalities).\n   3. Participants with QTcF \\>450 msec (if male) or \\>470 msec (if female) will be excluded.\n3. Resting HR \\\u003C 40 bpm or \\>100 bpm when vital signs are measured at Screening\n4. SARS-CoV-2 positive by PCR at Admission regardless of symptoms.\n5. Unstable cardiovascular disease, including recent (within 6 months of screening) myocardial infarction or cardiac arrhythmia.\n6. Ongoing liver disease or unexplained liver function test (LFT) elevations, defined as ALT, AST, gamma glutamyltransferase (GGT), alkaline phosphatase (ALP) or total\u002Fdirect bilirubin \\> upper limit of the reference range (ULRR) at Screening or Admission. Participants with confirmed Gilbert's syndrome will not be permitted to enroll in the study.\n7. Indications of pre-metabolic syndrome and\u002For systemic inflammation, as suggested by high-sensitivity C-reactive protein (hsCRP) of \\> 3 mg\u002FL, elevated erythrocyte sedimentation rate (Male ≥ 15 mm\u002Fhr, Female ≥ 20 mm\u002Fhr) or Hemoglobin A1c (HbA1c) \\>5.3% at Screening.\n8. History of cancer (malignancy) with the exception of basal or squamous cell carcinoma of the skin.\n9. Respiratory tract infection (upper and\u002For lower) treated with antibiotics within 12 weeks of Screening.\n10. Clinically significant infection or known inflammatory condition or history of clinically significant infection within 28 days prior to study drug administration on Day 1 that, in the opinion of the Investigator, would affect the participant's ability to participate in the trial.\n11. History of drug or alcohol abuse (as defined by DSM-V) within 12 months prior to Screening.\n12. Positive test result for alcohol (breath) or drugs of abuse (urine) at Screening or Admission.\n13. Positive serology result for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab) or human immunodeficiency virus antibody (HIV Ab) at Screening.\n14. Active or recent herpes simplex or herpes zoster infection, if considered clinically relevant as per investigator discretion.\n15. Venous access considered inadequate for PK sample collection; history of evidence of adverse symptoms associated with phlebotomy or blood donation.\n16. Participation in a study of any investigational drug, device, biologic or other agent within 30 days (or 5 half-lives, whichever is longer \\[as applicable\\]) prior to Day 1.\n17. Loss or donation of blood \\>500 mL (within 30 days prior to Screening); donation of bone marrow or peripheral stem cells (within 90 days prior to Day 1); or donation of plasma (within 7 days prior to Screening).\n18. No more than 10 standard drinks per week per NHMRC alcohol guidelines within 90 days prior to screening.\n19. Use of alcohol within 72 hours prior to study drug administration on Day 1.\n20. Use of prescription drugs within 14 days (or 5 half-lives, whichever is longer), or non-prescription drugs and\u002For herbal supplements within 7 days (or 5 half-lives, whichever is longer) prior to study drug administration on Day 1. Exception: hormonal contraceptives, acetaminophen ≤ 1 gram\u002Fday or ibuprofen ≤ 800 mg\u002Fday may be administered at Investigator's discretion.",true,"ALL","18 Years","55 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a single-centre, randomized, double-blind, placebo-controlled Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and multiple ascending oral doses to healthy adult participants aged 18-55 years.",[28,29,30,31],"Psoriasis (PsO)","Skin Disease","Immune System Disease","Skin Diseases, Papulosquamous",[33,34,35,36,37,38,39,40,41,42],"Phase 1","Healthy Participants","HL40626S","Oral Tablets","SAD","MAD","Safety","Pharmacokinetics","Immunogenicity","Pharmacodynamics","NOT_YET_RECRUITING","2026-07-31",{"date":46,"type":47},"2026-08-03","ACTUAL",{"date":49,"type":22},"2026-08",{"date":51,"type":22},"2027-05",{"name":53,"class":54},"HighsLab Therapeutics Inc.","INDUSTRY",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":55},"100482404","transdiagnostic-intervention-to-reduce-internalized-health-related-stigma-100482404","NCT05561595","Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma","HEARTS","Inclusion Criteria:\n\n* Age 18 years or older\n* Currently residing in the United States\n* At least one of the following stigmatized health conditions:\n* Obesity (or high body weight that negatively affects health)\n* Skin disease (including but not limited to psoriasis, eczema, or vitiligo)\n* Cancer (including but not limited to lung, breast, cervical, colorectal, gynecologic, prostate, or head and neck; including individuals in remission)\n* HIV\n* Type 1 or type 2 diabetes\n* Chronic pain\n* Reported internalization of health-related stigma, as determined by a pre-specified cutoff score on internalized stigma measure and confirmed by interview\n\nParticipants must have availability to attend weekly virtual group meetings for 12 weeks, followed by every-other-week and monthly meetings through 26 weeks, in the evening on a specified weekday. Participants must be willing to actively participate and share information about themselves in the group meetings.\n\nParticipants must be able to read, comprehend, and speak English in order to participate in group sessions and complete study questionnaires.\n\nParticipation requires an electronic device (computer, tablet, or phone) with video capabilities and internet, wi-fi, or cellular data in order to attend group sessions and complete study questionnaires. Individuals who do not have such devices or internet access will still be eligible to participate. In such cases, screening procedures will be conducted by phone, and randomized participants will be provided with web cameras or internet-enabled devices (and\u002For provided with pre-paid cellular data) to facilitate participation.\n\nExclusion Criteria:\n\n* Current or recent (e.g., past 3 months) receipt of psychotherapy or a psychosocial or peer support intervention (exceptions may be made if therapy or support is not focused on health conditions and is unlikely to affect internalized health-related stigma; e.g., family or marriage counseling, religious study groups, etc.)\n* Psychiatric hospitalization in the past 6 months\n* Recent (e.g., past 3 months, approximately) change in medications taken for psychiatric reasons\n* Current, active suicidal thoughts or suicide attempt within the past year\n* Current or past thought disorder or psychosis, or unmanaged bipolar disorder\n* Current alcohol\u002Fsubstance use disorder that requires immediate treatment\n* Health-related stigma due primarily to mental illness or substance use, or due to health conditions not specified in inclusion criteria.\n* No reported internalization of health-related stigma and\u002For score below pre-specified cutoff on internalized stigma measure\n* Unwilling or unable to complete study procedures\n\nParticipants with severe progression of disease (e.g., end-of-life) or who are undergoing acute, intensive treatment (such as chemotherapy or radiation therapy) will not be eligible to participate due to expected impacts on HRQOL and greater needs for psychological support than the intervention is intended to provide. Such participants may be eligible after completion of acute treatment or if severe symptoms remit and\u002For prognosis improves.",{"count":64,"type":22},195,[66],"NA","Stigma due to health conditions increases disease burden and adversely impacts health. The internalization of health-related stigma is associated with impaired mental health and quality of life. The current project will test the effects of a novel, transdiagnostic, group counseling intervention, and peer support, to determine the optimal method for helping patients cope with health-related stigma, reducing its internalization, and enhancing patient quality of life.",[69,29,70,71,72,73],"Obesity","Cancer","HIV","Diabetes","Chronic Pain","RECRUITING","2026-07-23",{"date":77,"type":47},"2026-07-24",{"date":79,"type":47},"2024-10-03",{"date":81,"type":22},"2027-06-30",{"name":83,"class":84},"University of Florida","OTHER",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":95,"conditions":96,"keywords":103,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":55},"100643462","coping-strategies-loneliness-and-resilience-in-patients-with-dermatosis-100643462","NCT07640373","Coping Strategies, Loneliness, and Resilience in Patients With Dermatosis","ESDaP3","Inclusion Criteria:\n\n* Patients with skin conditions (inflammatory, autoimmune, cancerous, or genetic skin disorders)\n* Controls: individuals without skin disease\n* Adult participant\n* Participant enrolled in a Social Security system or equivalent\n* Participant who has given consent to participate in the study\n\nExclusion Criteria:\n\n* Participants who are unable to understand the protocol\n* Participants under legal guardianship (guardianship, conservatorship)\n* Participants subject to a future protection order, family authorization, or court-ordered protection\n* Participants who are unable to complete the questionnaires",{"count":93,"type":22},375,[66],"The European Society for Dermatology \\& Psychiatry (ESDaP) studies the connection between the skin and the mind. Two previous studies of this type were conducted in 13 and 15 European countries, respectively. The first study assessed the psychological impact of skin diseases (anxiety, depression, sleep disorders), and the second analyzed feelings of stigma, stress, and body dysmorphic disorder (an abnormal perception of one's body).\n\nIn this study, new psychological variables will be examined: coping strategies, loneliness, and resilience.\n\nA total of 23 centers will participate in the ESDaP3 study, located in 15 European countries (Austria, France, Germany, Hungary, Italy, North Macedonia, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Turkey, and the United Kingdom).\n\nThe aim of this study is to examine coping strategies, loneliness, and resilience among patients with a skin condition. Coping strategies refer to the various ways a person uses to manage a difficult or stressful situation. Resilience refers to a person's ability to cope with difficult situations, adapt to changes or challenges, and regain a sense of balance despite obstacles. Other factors will be assessed: sleep, anxiety and depression, and quality of life. A questionnaire will be given to your potential partner to assess the impact of the skin condition on their life at this time.\n\nAt the study's sole French site, Brest University Hospital, 250 patients with a skin condition and 125 people without a skin condition will be enrolled.",[29,97,98,99,100,101,102],"Skin Disorder","Skin Condition","Inflammatory Skin Conditions","Autoimmune Skin Diseases","Cancerous Skin Conditions","Genetic Skin Conditions",[104,105,106],"Adaptation strategies","loneliness","resilience","2026-06-05",{"date":109,"type":47},"2026-06-10",{"date":111,"type":22},"2026-07",{"date":113,"type":22},"2029-10",{"name":115,"class":84},"University Hospital, Brest",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":55},"100609011","dynamics-of-dysbiosis-in-the-skin-and-gut-microbiome-of-burn-patients-100609011","NCT07209007","Dynamics of Dysbiosis in the Skin and Gut Microbiome of Burn Patients","An Exploratory Study on the Dynamics of Microbiome Dysbiosis (Microbial Imbalance) in the Skin and Gut Microbiome of Burn Patients","BURN-MICRO","Inclusion Criteria\n\n* Adults aged 19 to 65 years\n* Patients with partial- or full-thickness burns whose wounds have completely healed following debridement, grafting, or conservative treatment\n* Ability to understand study objectives and provide written informed consent\n\nExclusion Criteria\n\n* Use of systemic or topical antibiotics, probiotics, steroids, or immunosuppressants within 2 weeks prior to sample collection\n* Pregnancy or breastfeeding\n* Chronic skin diseases (e.g., psoriasis, eczema) or systemic illnesses affecting the skin microbiome\n* Active infections at the sampling site\n* Any medical condition judged by the investigator to make participation inappropriate","19 Years","65 Years",{"count":127,"type":22},600,"OBSERVATIONAL","This prospective observational cohort study aims to investigate the longitudinal changes in the skin and gut microbiome of burn patients after injury and compare them with healthy controls. Burn injuries are known to induce systemic physiological and immune responses that may lead to widespread microbial dysbiosis (microbial imbalance) beyond the injured site. However, the dynamics of microbial community changes in both burned and non-burned skin, as well as the gut, remain poorly understood.\n\nIn this study, a total of 660 participants will be enrolled, including 600 burn patients and 60 healthy controls. For burn patients, skin swabs from burned scars and matched non-burned skin, stool samples, and physiological skin measurements will be collected at multiple time points (baseline, 3 months, 6 months, 12 months, and 24 months). Healthy controls will provide skin and stool samples at baseline only.\n\nMicrobial profiling will be performed using 16S ribosomal RNA (rRNA) gene sequencing, and functional prediction will be analyzed using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2). Physiological skin-barrier measurements, including transepidermal water loss (TEWL), hydration, pH, erythema, and elasticity, will be assessed using standardized instruments. Blood biomarkers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), will also be measured.\n\nThe findings of this study will improve our understanding of burn-related microbial dysbiosis, provide insights into microbiome-driven skin-barrier recovery, and inform potential therapeutic strategies for long-term burn care.",[131,29,132,133],"Burn Injuries","Microbiome","Microbiome Dysbiosis",[135,136,137,138,139],"Burn Injury","Skin Microbiome","Gut Microbiome","Dysbiosis","16S rRNA Sequencing","2025-09-29",{"date":142,"type":47},"2025-10-06",{"date":144,"type":47},"2025-09-15",{"date":146,"type":22},"2030-12-31",{"name":148,"class":84},"Cho Yoon soo"]